Q-omics provides the consensus-scored MIR124-1HG profile across patient tissues and cancer cell-line models. MIR124-1HG expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, MIR124-1HG is differentially expressed in 6, with the highest sampling consensus in PAAD. Additionally, MIR124-1HG RNA expression shows 10,926 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight DLBC, PAAD, and GBM as cancer lineages where MIR124-1HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR124-1HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR124-1HG survival associations across molecular data types. MIR124-1HG RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR124-1HG RNA expression–survival associations across cancer types. High MIR124-1HG expression shows unfavorable associations in DLBC, ACC, UVM and LUAD, but favorable associations in LGG and BLCA. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for MIR124-1HG RNA expression.
This table summarizes MIR124-1HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR124-1HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR124-1HG shows lower tumor expression in PAAD, BRCA, KICH, KIRP and READ and higher tumor expression in HNSC. The PAAD box plot shows higher MIR124-1HG RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p = .019).
This table shows molecular features associated with MIR124-1HG in patient tissues and cancer cell lines. In patient samples, MIR124-1HG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
